Trial Profile

A phase I/II single arm study on the efficacy of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belantamab mafodotin (Primary) ; Carfilzomib (Primary) ; Dexamethasone (Primary)
Indications Multiple myeloma
Focus Biomarker; Therapeutic Use
Acronyms BelaCarD

12 Dec 2023 Results assessing a planned interim analysis of safety and responses after the first two cycles of combination therapy were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
17 Jun 2022 Results (data cut off: Feb 3rd 2022; n=19) assessing safety, tolerability, and preliminary efficacy of BelaMaf in combination with carfilzomib and dexamethasone (Kd) in patients with early relapsed MM presented at the 27th Congress of the European Haematology Association
02 May 2022 Planned number of patients changed from 70 to 68.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com